Asymchem Laboratories (Tianjin) (002821) Q2 2026 earnings summary

Executive summary

• Revenue for the first half of 2026 reached ¥3.61 billion, up 13.13% year-over-year, with strong growth in both traditional and emerging business lines.

• Net profit attributable to shareholders was ¥520 million, down 15.71% year-over-year, mainly due to exchange rate fluctuations.

• Adjusted net profit (excluding non-recurring items) was ¥753 million, up 12.90% year-over-year.

• The company maintained its position as a leading global CDMO, expanding its customer base and accelerating new business development.

Financial highlights

• Operating cash flow increased 17.18% year-over-year to ¥822 million.

• Gross margin was 42.27%, with a slight increase under constant currency.

• Basic and diluted EPS were ¥1.45, down 13.69% year-over-year.

• Total assets at period-end were ¥20.83 billion, up 2.73% from year-end 2025.

• Net assets attributable to shareholders rose 0.59% to ¥17.74 billion.

Outlook and guidance

• Full-year 2026 revenue is expected to grow 19–22% year-over-year.

• Order backlog (excluding recognized revenue) reached $1.673 billion, up 53.77% year-over-year.

• New orders signed year-to-date increased 54.59% year-over-year, with rapid growth in chemical and biological macromolecule businesses.